tiprankstipranks
Eupraxia Pharmaceuticals (EPRX)
NASDAQ:EPRX
US Market
EPRX
Eupraxia Pharmaceuticals
RESEARCH TOOLSreports
Want to see EPRX full AI Analyst Report?

Eupraxia Pharmaceuticals (EPRX) Income Statement

36 Followers

Eupraxia Pharmaceuticals Income Statement

Last quarter (Q4 2025), Eupraxia Pharmaceuticals's total revenue was C$0.00, a decrease of ― from the same quarter last year. In Q4, Eupraxia Pharmaceuticals's net income was C$-16.97M. See Eupraxia Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Mar 24Dec 22Dec 21
Total Revenue
C$ 0.00C$ 0.00C$ 0.00C$ 0.00C$ 0.00
Gross Profit
C$ -241.88KC$ -235.25KC$ -209.91KC$ -193.27KC$ -111.53K
Operating Expenses
C$ 38.86MC$ 36.76MC$ 37.92MC$ 23.20MC$ 18.68M
Depreciation and Amortization
C$ 241.88KC$ 235.25KC$ 209.91KC$ 193.27KC$ 111.53K
EBITDA
C$ -38.86MC$ -33.72MC$ -37.40MC$ -22.14MC$ -21.96M
Operating Income
C$ -39.11MC$ -36.99MC$ -36.90MC$ -22.63MC$ -20.87M
Other Income/Expenses
-C$ 1.73MC$ -2.29MC$ -64.07KC$ -5.46M
Pretax Income
C$ -39.26MC$ -35.27MC$ -39.18MC$ -23.92MC$ -23.37M
Net Income
C$ -39.25MC$ -34.94MC$ -37.39MC$ -23.26MC$ -22.99M
Per Share Metrics
Basic EPS
C$ -1.05C$ -1.03C$ -1.58C$ -1.21C$ -1.61
Diluted EPS
C$ -1.05C$ -1.03C$ -1.58C$ -1.21C$ -1.61
Weighted Average Shares Outstanding
 39.96M 33.93M 24.15M 19.29M 14.24M
Weighted Average Shares Outstanding (Diluted)
 39.96M 33.93M 24.15M 19.29M 14.24M
Currency in CAD

Eupraxia Pharmaceuticals Earnings and Revenue History